ABSTRACT. Despite recent advances in osteosarcoma diagnosis and therapy, much remains unclear about the molecular mechanisms involved in the disorder, and the discovery of novel drug-targeted genes is essential. We explored the potential molecular mechanisms and target genes involved in the development and progression of osteosarcoma. First, we identified the differentially expressed genes in osteosarcoma patients and matching normal controls. We then constructed a differential expression network based on differential and non-differential interactions. Pathwayenrichment analysis was performed based on the nodes contained in the main differential expression network. Centrality analysis was used to select hub genes that may play vital roles in the progression of human osteosarcoma. Our research revealed a total of 176 differentially expressed genes including 82 upregulated and 94 downregulated genes. A differential expression network was constructed that included 992 gene pairs (1043 nodes). Pathway-enrichment analysis indicated that the nodes in the 17709 Key genes associated with osteosarcoma ©FUNPEC-RP www.funpecrp.com.br Genetics and Molecular Research 14 (4): 17708-17717 (2015) differential expression network were mainly enriched in several pathways such as those involved in cancer, cell cycle, ubiquitin-mediated proteolysis, DNA replication, ribosomes, T-cell receptor signaling, spliceosomes, neurotrophin signaling, oxidative phosphorylation, and tight junctions. Six hub genes (APP, UBC, CAND1, RPA, YWHAG, and NEDD8) were discovered; of these, two genes (UBC and RPA) were also found to be disease genes. Our study predicted that UBC and RPA had potential as target genes for the diagnosis and treatment of osteosarcoma.
INTRODUCTION
Osteosarcoma (OSA) is the most frequently diagnosed primary bone tumor, and mainly occurs in children and young adults, with a second peak in middle age (Osaki et al., 2011) . OSA is characterized by aberrant proliferation of malignant mesenchymal cells accompanied by the production of an osteoid matrix, immature bone, and intricate karyotypes (Federman et al., 2009 ). The tumor is characterized by very high morbidity, early location metastasis, and poor survival rate (Nagarajan et al., 2011; Salah et al., 2014) . Currently, the prognosis for patients with metastatic diseases including OSA remains serious. Although many studies have described significant advances in surgery and adjuvant chemotherapy in OSA (Bacci et al., 2006; D'Adamo, 2011) , surgery cannot halt the rapid metastasis of the tumor lesions, and chemotherapy is largely restricted by the development of resistance and severe side effects. Therefore, the discovery of new targets that have potential for OSA diagnosis and therapy is imperative.
Gene copy number alterations in OSA have been confirmed by comparative genomic hybridization (CGH) and single-nucleotide polymorphism (SNP) microarray analysis following the introduction of high-speed and high-throughput DNA microarray technologies. It is universally acknowledged that the occurrence and development of OSA is closely associated with the chromosome arms 6p, 8q, and 17p, and there are many additional reported regions (Squire et al., 2003; Kresse et al., 2010) . The effects of copy number changes can be demonstrated by the upregulation or downregulation of gene expression levels in the affected chromosomal regions. To date, various published works have focused on analyzing OSA-related gene expression individually, but few researchers have explored the underlying mechanisms and target genes of OSA using robust bioinformatics.
Recently, a "differential network" (DN) technique (Ideker and Krogan, 2012) has been developed to extract disease-related edges by comparing interactions occurring across different static networks. Since genes and gene products operate not as a single unit but as part of a biochemical interaction, we assume that molecular interactions are disrupted by epigenetic or genetic factors; the disruption ultimately leads to molecular dysfunction. Therefore, the "dysfunctional interaction" concept, defined by the molecular interactions that show obvious differences between the wild-type and the disease condition, is proposed as a means of modeling the underlying human disease development and progression. However, a molecular interaction comprises two nodes and one edge, and the quantitative assessment of its change under different conditions is not straightforward. We combine the two types of perturbations when referring to "dysfunctional interaction". Type I dysfunctional interactions are caused by edge perturbations. In other words, the co-expression relationship of the molecular interaction is changed differentially, and it is called a "differential interaction" because it directly changes the molecular interactions. Type II dysfunctional interactions are called "non-differential interactions" because they indirectly affect interactions through node changes. Note that non-differential interactions involve an edge that lacks significant differential strength, but its two linked nodes are both differentially expressed genes, and are therefore closely associated with biological processes. With the dysfunctional interaction concept, a novel type of molecular network, the "differential expression network" (DEN), has been developed. Compared with the traditional differential gene (DG) and DN techniques, DEN is better at describing the phenotype differences at the network level. From the network perspective, DEN not only includes DG and DN, but also covers "non-differential interactions", which are all missed by the DN method.
In this study, we constructed a DEN by extracting "differential interactions" and "nondifferential interactions", which are capable of characterizing the initiation and progression of OSA. First, we downloaded the microarray data of the OSA model and sham controls from the ArrayExpress database. The altered expression profile was analyzed to identify the differentially expressed genes (DEGs). Additionally, the DEN was built based on the protein-protein interactions (PPI) combined with the gene expression profiles to determine hub genes via the degree centrality analysis of the DEN. Furthermore, we employed Database for Annotation, Visualization and Integrated Discovery (DAVID) software to show the significant Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways included in the DEN revealing abnormal biological processes. In our study, the elucidation of genes and pathways using the DEN method revealed potential new therapeutic targets.
MATERIAL AND METHODS

Data source
We extracted the gene microarray expression profiles of osteoblasts and mesenchymal stem cells (MSCs) E-GEOD-33382 (Kresse et al., 2010) from the ArrayExpress database (http:// www.ebi.ac.uk/arrayexpress/). Gene expression analysis was performed on the seven normal controls and pretreatment diagnostic biopsies of 84 resectable osteosarcoma samples (Kresse et al., 2010) . The clinical details of these samples are listed in Table 1 . All the microarray datasets in CEL form and annotation information were downloaded for further exploration.
Screening of DEGs
After obtaining the raw expression datasets, quartile data normalization was performed using the Robust Multi-array Average (RMA) method (Ma et al., 2006) . We then used the Student t-test to identify DEGs between OSA patients and normal controls (Ritchie et al., 2007) . Finally, we selected the DEGs with values meeting the cut-off criteria (P value of less than 0.05 and |log-fold change (FC)| larger than 2).
Generic PPI network
Because proteins rarely exert their functions individually, it is very important to explore protein interactions by studying functional protein groups (Srihari and Leong, 2012) . For this paper, we downloaded the whole PPI datasets from the Biological General Repository for Interaction Datasets (BioGrid, http://thebiogrid.org/). Cytoscape 2.1 software was employed to establish PPI networks (Shannon et al., 2003) . In the original PPI network, a total of 15,750 genes and 248,584 interactions were contained in the BioGrid. Based on the transcript data of E-GEOD-33382, we then secured another PPI network including 10,084 genes and 11,6546 interactions. 
Calculating Spearman correlation coefficients of gene pairs
The Spearman correlation coefficient method was applied to evaluate the strength of gene interactions. For each edge in the PPI network, the Spearman correlation coefficient was calculated separately using gene expression values under different conditions (healthy controls and OSA patients), which served as A1 and A2, respectively.
Determining the threshold of differential interaction
Two models (one for cases, the other for controls) were established randomly, and each model contained 200,000 gene pairs. The Spearman correlation coefficients in the two models (A1, A2) were computed. The absolute correlation coefficient values (|A1-A2|) were obtained. After aligning the absolute correlation coefficient values in descending order and setting the P value threshold at 0.01, we observed that the absolute value was 1.422. The Spearman value of the 116,546 relationships based on BioGrid and transcript data were arrayed in descending order. We selected those differential relationships that had an absolute correlation coefficient value of greater than 1.422, and at least one Spearman correlation coefficient of greater than 0.7.
Construction of DEN
The edges with absolute correlation coefficient values of greater than 1.422 and at least one of A1 or A2 greater than 0.7 were considered to represent differential interactions. Other gene pairs with |A1-A2| values of less than or equal to 1.422 and two nodes that were both DEGs were taken to represent non-differential interactions. The DEN was constructed by incorporating all the differential and non-differential interactions. The network was constructed using Cytoscape 2.1 software.
Node centrality analysis
We used classical network centrality analysis in this study. Network centrality analysis, in which each centrality presents a possible biological meaning in a protein network, plays a significant role in the investigation of biological networks. The centrality method involves degree centrality, closeness centrality, betweenness centrality, etc. As the simplest topological index, the degree corresponds to the number of adjacent nodes, where "adjacent" means directly connected (Koschützki and Schreiber, 2008) . Nodes with a high degree are called "hub genes", and combine some nodes with a lower degree, thereby indicating a central role in the network (He and Zhang, 2006) . Networks that display a distribution approximating a power law are referred to as scale-free networks (Pietsch, 2006) . A scale-free network is typically a natural network, is mainly dominated by hub genes, and is intrinsically robust to random attacks, but is susceptible to selected alterations (Jeong et al., 2001 ).
Identification of the disease genes contained in the DEN
We downloaded the genes associated with OSA (denoted as "disease genes" for convenience in this study) from the GeneCards database at the website http://www.genecards. org/. GeneCards is a recognized and comprehensive human gene database that provides all known and predicted transcriptomic, genomic, proteomic, and functional genetic information (Harel et al., 2009 ). The disease genes underlying disease development and progression in the DEN were selected in a complex statistical way.
Pathway-enrichment analysis
The KEGG pathway database is a comprehensive and authoritative database that provides almost all biochemical pathways. In our study, the online DAVID software, which includes a set of novel and powerful tools, was used for KEGG pathway enrichment to identify the main biochemical pathways for the nodes in DEN (Huang et al., 2007) . We selected P values of less than 0.01 and gene counts of larger than or equal to 9 as the cut-off criteria for KEGG pathwayenrichment analysis.
RESULTS
Identification of DEGs
Based on the statistical analysis of microarray datasets between OSA patients and the normal controls, a total of 176 DEGs (82 upregulated and 94 downregulated genes) were screened according to the criteria: |logFC| > 2.0 and P value <0.05.
Construction of DEN
As described above, the DEN should be constructed by complementarily considering both differential and non-differential interactions. We identified 966 differential interactions with |A1-A2| >1.422 and at least one of A1 or A2 >0.7. Moreover, there were 26 gene pairs with |A1-A2| values of less than or equal to 1.422 but with corresponding nodes that were both DEGs. In other words, there were 26 non-differential interactions. Therefore, a DEN including 992 gene pairs (1043 nodes) was constructed. The main DEN is shown in Figure 1 . By comprehensive statistical analysis, we constructed a DEN comprising 101 disease genes constituting 247 disease gene pairs. 
Centrality analysis to obtain hub genes
Analysis of the nodes degree of the DEN revealed that the degree distribution was close to a power law, illustrating that the DEN was a scale-free network, as depicted in Figure 2 . Six genes (APP, UBC, CAND1, RPA, YWHAG, and NEDD8) with high connectivity degree (>14) were selected as the hub nodes and might play an important role in the progression of OSA. The connectivity degrees of the hub genes are shown in Table 2 . Two of the hub genes, UBC and RPA, are also disease genes, which indicates their more crucial role in the oncogenesis of OSA. Table 2 . Statistical results of connectivity degrees and other information of hub genes. DEGs = differentially expressed genes. Gene symbols also represent the corresponding proteins; degree represents the degree of connectivity for each gene.
KEGG pathway-enrichment analysis
To gain further insight into the function of the nodes in the DEN, the DAVID software was used to determine the significant dysregulated KEGG enrichment pathways. The obtained pathways with P values < 0.01 and gene counts ≥9 are shown in Table 3 . From the results, we can see that the genes in the DEN were mainly enriched in pathways involving cancer, the cell cycle, ubiquitin-mediated proteolysis, DNA replication, ribosomes, T-cell receptor signaling, spliceosomes, neurotrophin signaling, oxidative phosphorylation, and tight junctions.
DISCUSSION
OSA is the most common malignant bone cancer that occurs in humans. Although the aggressive use of surgical techniques and chemotherapy have improved survival, the prognosis for OSA patients remains poor, and treatment still presents severe challenges (Akiyama et al., 2008) . Therefore, more effective anti-OSA targets are urgently sought.
In this study, we researched the gene expression profiles of OSA through DEN, expecting to select target genes associated with OSA. Analysis of the constructed DEN revealed that six genes (APP, UBC, CAND1, RPA, YWHAG, and NEDD8) were hub nodes and none was a DEG. DEGs, showing significantly different expression profiles in the case and control groups, are usually found using traditional statistical techniques, such as the t-test or fold change (Goñi et al., 2008; Ray and Zhang, 2010) . Although DEGs are regarded as candidates for a role in pathogenesis, they are generally selected out separately, while co-expression of genes is ignored (Kostka and Spang, 2004) . In this paper, six hub genes, not including the DEGs, were screened by DEN, which comprised "differential interactions" and "non-differential interactions". DEN, which complements traditional methods, can be used to interpret gene interactions from a new perspective. Among the six hub genes obtained using DEN, UBC and RPA were also disease genes, which suggested that UBC and RPA might be more selectively involved in OSA.
By performing KEGG pathway enrichment analysis of the nodes contained in DEN, we found that the hub gene UBC participates in the ubiquitin-mediated proteolysis pathway. The expression of ubiquitin-conjugating enzyme (E2) UBC13, which belongs to the UBC family, is significantly upregulated in metastatic breast cancer (Fidler, 2003) . UBC13 first heterodimerizes with Uev1a and then catalyzes the formation of lysine 63-linked polyubiquitin chains, which govern the PPIs associated with protein kinase activation and DNA damage repair (Bhoj and Chen, 2009; Wang et al., 2012) . For some immune cells, UBC13 is indispensable for IκB kinase (IKK)-NF-κB activation, but a more important function of UBC13 is the activation of the MAPK signaling pathway (Yamamoto et al., 2006a; Yamamoto et al., 2006b) . It has been reported that UBC13 is also required for triggering MEKK1 (mitogen-activated protein kinase kinase kinase 1), TGFβ (transforming growth factor β)-activating kinase 1 (TAK1), and the downstream MAPK cascade (Matsuzawa et al., 2008) . Crucially, MEKK1 and TAK1 are also required for the metastasis of cancer cells (Cuevas et al., 2006; Safina et al., 2008) . A recently published paper showed that UBC13 controls breast cancer metastasis via TAK1-p38 MAP kinase cascades (Wu et al., 2014) .
The KEGG functional enrichment results showed that RPA is involved in the DNA replication pathway. RPA is a heterotrimeric ssDNA-binding protein and plays a crucial role in S-phase DNA replication, DNA excision repair, DNA recombination, and other DNA metabolic pathways (Wold, 1997; Fanning et al., 2006) . Additionally, RPA is involved in the ATR/Chk1 pathway and it recruits and interacts with other proteins, such as ATRIP, Nbs1, Rad17, and Rad9, that are required for the replication stress response Majka et al., 2006; Xu et al., 2008; Oakley et al., 2009) . Recruitment of ATRIP, Nbs1, Rad17, and Rad9 entails the loading of TopBP1 followed by the activation of ATR Xu et al., 2008; Shiotani et al., 2013) . This triggers a critical surveillance network of signaling pathways that mediate the cellular response to replication stress. Cancer cells with activated oncogenes cause a massive increase in stress during replication. Compared with normal cells, the presence of higher replication stress levels in cancer cells opens up a therapeutic opportunity to target RPA for preferentially killing cancer cells.
CONCLUSION
In light of the preliminary study, we discovered that the pathogenesis of osteosarcoma is closely related to several other pathways including those involving cancer, the cell cycle, ubiquitinmediated proteolysis, DNA replication, and ribosomes. Based on the DEN, we also confirmed that six genes (APP, UBC, CAND1, RPA, YWHAG, and NEDD8) might play key roles in osteosarcoma, and that two genes (UBC and RPA) have potential as biomarkers for the diagnosis and treatment of human osteosarcoma.
